Back to results
US 11,771,705 B2Granted
Adjuvant therapy for use in prostate cancer treatment
AssigneeFund SA
InventorF. M. J. Debruyne
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of prostate cancer treatment, and in particular the field of prostate cancer treatment by Androgen Deprivation Therapy (ADT). The present treatment involves oral administration of an estetrol component in conjunction with ADT.
Claims5
A method of treating prostate cancer in a patient undergoing androgen deprivation therapy (ADT), comprising:
- (i) administering to the patient a GnRH agonist selected from the group consisting of buserelin, goserelin, leuprolide, nafarelin, and triptorelin, or a GnRH antagonist selected from the group consisting of cetrorelix, ganirelix, abarelix, degarelix, elagolix, relugolix, KLH-2109 (linzagolix), and ASP-1707 (opigolix), and
- (ii) orally co-administering estetrol in a daily dose of 20 mg to 60 mg for at least 4 weeks,
- wherein the co-administration causes a further decrease of free testosterone levels compared to administration of the GnRH agonist or the GnRH antagonist alone.
Dependencies are inferred from the claim text.